Vir Biotechnology
VIR8.6402.37% ( -0.210 )
Vir Biotechnology (VIR)
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious disease...
- Open
- 8.840
- High
- 8.970
- Low
- 8.550
- Prev. Close
- 8.850
- Volume
- 1.41M
- Turnover
- 12.25M
- Avg Price
- 8.671
- Bid/Ask Ratio
- --
- Amplitude
- 4.75%
- 52wk High
- 11.660
- Volume Ratio
- 0.80
- Turnover Ratio
- 1.19%
Vir Biotechnology Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$21.56149.49%
Forecast & RatingStrong buy
10analysts
- Strong buy70.00%
- Buy30.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 24 at 07:30 AM
Vir Biotechnology names Brent Sabatini interim principal financial officer as CFO exits
- StockTitan · Jul 23 at 11:30 PM
Vir Biotechnology Announces Chief Financial Officer Transition | VIR Stock News
- PUBT · Jul 22 at 03:07 PM
Vir Biotechnology schedules conference call on second-quarter 2026 results
- PR Newswire · Jul 2 at 07:00 PM
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
- PUBT · Jul 2 at 05:56 PM
Brii Biosciences says arbitration with Vir clouds future of elebsiran program
- Market Beat · Jun 11 at 07:47 AM
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00
